An observational study in Fibromyalgia, sponsored by Arafarma Group, S.A.. Completed at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-10.
Sponsored by Arafarma Group, S.A. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Fibromyalgia with a site in Spain — 16 open to participants now, 21 under way, none of them phase 3. Fibromyalgia · Spain.
Among the 151 studies in Fibromyalgia with a site in Spain, this one is the 13th largest by enrollment of the 15 observational ones that give a count, is one of 18 that started in 2022, is one of 15 observational ones, and was the 111th registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →16 of the 151 studies in Fibromyalgia with a site in Spain are open now. Recruiting first, the newest first:
Ionclinics & Deionic SL · Sites in Spain
Ages 18+
European University Miguel de Cervantes · Sites in Spain
Ages 18+ · Women only
University of Valladolid · Sites in Spain
Ages 18+
Cardenal Herrera University · Sites in Spain
Ages 18–80
Parc de Salut Mar · Sites in Spain
Ages 18–70 · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 18 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 100 across 280 observational studies indexed under Fibromyalgia.
Median enrollment 66 across the 135 interventional studies, 90 across the 15 observational. Of the 107 that completed or were terminated, 10 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 151 have an industry lead sponsor. The 10 most frequent:
Arafarma Group, S.A. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Arafarma Group, S.A. has 1 study filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Fibromyalgia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424534University of Castilla-La ManchaPredictive Models on Psychosocial Profile, Fatigue and Sleep Quality | 2026-11-30 |
| NCT06948500Cardenal Herrera UniversityEffectiveness of an IVR-based Therapeutic Exercise Program With Altered Visual Feedback in Fibromyalgia Patients | 2026-12-01 |
| NCT07693998University of ValenciaPain Neuroscience Education for Chronic Pain | 2026-12-31 |
| NCT04084795Parc de Salut MarAugmentation of EMDR With tDCS in the Treatment of Fibromyalgia | 2026-12-31 |
| NCT05962437Fundació Sant Joan de DéuSelf-guided Acceptance and Commitment Therapy-based Digital Smartphone Application for Management of Fibromyalgia | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 151 studies in Fibromyalgia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fibromyalgia is a syndrome (set of symptoms) of unknown etiology and characterized by diffuse musculoskeletal pain and chronic fatigue. In addition, other symptoms such as cognitive alterations, sleep rhythm disturbances, psychiatric syndromes such as anxiety, depression, etc. Other very characteristic symptoms are hyperalgesia (very low pain threshold) and allodynia (amplified response to painful stimuli).
The treatment of fibromyalgia is symptomatic and the drugs only serve to reduce symptoms in some patients, in addition to the fact that these available treatments (antidepressants, pain signal modulators, rescue analgesics, etc.) have many side effects.
The food supplement which is the object of this study, FibrofixPlus®, is made up of a combination of natural substances.
This is the reason why this observational study aims to improve symptoms caused by fibromyalgia in patients treated with FibrofixPlus®.
Patients who meet the fibromyalgia criteria according to the definition of the American College of Rheumatology (ACR) in 1990 and 2010, with a minimum score of 4 on the Visual Analogue Scale (VAS) of Fatigue and Pain and without any treatment (anxiolytics, neuroleptics, antidepressants and/or narcotic analgesics) in a minimum of 4 weeks prior to the beginning of the study, with some exceptions, and who do not meet any of the exclusion criteria will be invited to participate in the study.
There are three study visits which are distributed throughout 8 weeks.
Women with fibromyalgia in primary care clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will be administered with one sachet of food supplement (FibrofixPlus®) per day, for 8 weeks.
Dietary Supplement: Food supplement
FibrofixPlus® is an authorized food supplement.
Symptomatic change of fibromyalgia through the Fibromyalgia Impact Questionnaire (s-FIQ), after taking the FibrofixPlus® food supplement, for 8 weeks.
To assess the magnitude of the symptomatic improvement by measuring the results to questions of the Fibromyalgia Impact Questionnaire (s-FIQ). This questionnaire scores from 0 to 100, being 0 the best quality of life and functional capacity, and 100 is the worst result.
Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Rate of safety episodes.
All episodes will be recorded, whether considered minor or serious, food supplement-related or not.
Time frame: Visit 1 to Visit 2, up to 4 weeks.
Change of fatigue symptom through the Visual Analogue Scale (VAS).
To assess the fatigue symptom by the completion of the Visual Analogue Scale (VAS). The VAS scores from 0 to 10, being 0 the best outcome (without fatigue) and 10 the worst outcome (maximum fatigue).
Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change of fatigue symptom through the Symptom Severity Score (SS Score).
To assess the fatigue symptom by the completion of the Symptom Severity Score (SS Score). The SS Score has a scoring from 0 to 12, being 0 the best outcome (without fatigue) and 12 the worst outcome (maximum fatigue).
Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change of pain symptom through the Visual Analogue Scale (VAS).
To assess the pain symptom by the completion of the Visual Analogue Scale (VAS). The VAS scores from 0 to 10, being 0 the best outcome (without fatigue) and 10 the worst outcome (maximum fatigue).
Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change of pain symptom through the Widespread Pain Index (WPI).
To assess the pain symptom by the completion of the Widespread Pain Index (WPI). The WPI scores from 0 to 19, being the highest result the worst outcome as defined by the number of body areas with pain.
Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change of pain symptom through the Symptom Severity Score (SS Score).
To assess the pain symptom by the completion of the Symptom Severity Score (SS Score). The SS Score has a scoring from 0 to 12, being 0 the best outcome and 12 the worst outcome.
Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change of the sleep quality through the Pittsburgh Sleep Quality Index (PSQI).
To assess the sleep quality by the completion of the Pittsburgh Sleep Quality Index (PSQI). The PSQI has a scoring from 0 to 21, being 0 the best outcome with no difficulties to sleep.
Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change of the sleep quality through the Symptom Severity Score (SS Score).
To assess the sleep quality by the completion of the Symptom Severity Score (SS Score). The SS Score has a scoring from 0 to 12, being 0 the best outcome and 12 the worst outcome.
Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change on the functional impairment through the questionnaire Clinical Global Impressions (CGI).
To assess the functional impairment by the completion of the Clinical Global Impressions (CGI). The CGI has a scoring from 0 to 7, being 0 "not assessed" and 1 "normal or not ill" and 7 "extremely ill".
Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change on the functional impairment through the questionnaire Short Form-36 Questionnaire (SF-36).
To assess the functional impairment by the completion of the Short Form-36 Questionnaire (SF-36). The SF-36 has several questions so when the scoring is higher, better is the health status. The global score is between 0 and 100, being 0 the worst and 100 the best health status.
Time frame: At Visit 0 and at Visit 2, or 8 weeks after Visit 0.
Change on the quality of life through the questionnaire Clinical Global Impressions (CGI).
To assess the quality of life by the completion of the questionnaire CGI. The CGI has a scoring from 0 to 7, being 0 "not assessed" and 1 "normal or not ill" and 7 "extremely ill".
Time frame: From Visit 0, and at each visit (Visit 1 or 4 weeks after Visit 0; and Visit 2 or 8 weeks after Visit 0).
Change on the quality of life through the questionnaire Hospital Anxiety and Depression Scale (HADS).
To assess the quality of life by the completion of the HADS. The HADS has a maximum score of 21, which indicates a severe or worse status.
Time frame: At Visit 0 and at Visit 2, or 8 weeks after Visit 0.
Change on the quality of life through the questionnaire Short Form-36.
To assess the quality of life by the completion of the Short Form-36 Questionnaire (SF-36). The SF-36 has several questions so when the scoring is higher, better is the health status. The global score is between 0 and 100, being 0 the worst and 100 the best health status.
Time frame: At Visit 0 and at Visit 2, or 8 weeks after Visit 0.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Mar 2022 to primary completion in Sep 2022, 5 months.
Of 88 observational studies under Fibromyalgia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 91. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arafarma Group, S.A.